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EXECUTIVE SUMMARY 
 
 
The first Stakeholder meeting of the Marine Biotechnology ERA-NET (ERA-MBT), held in Lisbon, 
Portugal, on the 28th and 29th October of 2014, gave participants an opportunity to influence the 
future of the ERA-MBT and to reinforce the network of researchers, industry, policy makers and 
funding agencies to support the development of European marine biotechnology.  
Please note that pdf files of the presentations are given at the ERA-MBT web page 
www.marinebiotech.eu/stakeholder-meeting.  
 
STATE OF THE ART OF MARINE BIOTECHNOLOGY 
Several invited speakers gave an overview of different areas contributing to the state of the art of 
marine biotechnology. In contributing a policy perspective, Jacques Fuchs, Deputy Head of Unit F4 
- Marine Resources, DG Research and Innovation, European Commission, described the range of 
EC support actions that contribute to marine and maritime development, and how the Jean-Claude 
Junker led Commission, provides many new opportunities for marine biotechnology, since funding 
for top-level research not only creates jobs, but also ensures that technological progress gives a 
boost to the economy. 
Torger Børresen of Innovation Fund Denmark, the Danish ERA-MBT partner, highlighted the 
marine biotechnology product opportunities and illustrated the market penetration of products 
originating from the marine environment in areas such as biomaterials, food, pharmaceuticals, etc. 
The adoption of an even-more strategic approach that would support a “market driven approach” to 
marine biotechnology would bring a greater research focus to marine biotechnology, and for an 
optimal use of any raw material it would be necessary to target several markets in a multi-stream 
processing approach. Rachael Ritchie, Director, Business Development, Genome, British Columbia 
in Canada provided an international perspective on the state of the art of marine biotechnology. In a 
wide-ranging and stimulating talk, she covered all aspects of the marine biotechnology value chain 
from addressing the need for expanding the –omics toolbox to the investment potential, governance 
challenges, sustainability and impacts on global needs. 
Bioprocessing of marine biomass may also present a lot of challenges. Dagmar Stengel, National 
University of Ireland Galway, showed how algal biomass on one side is an excellent material for 
biorefining into a range of products, and on the other side, the ecosystem services they offer. Among 
the challenges in biorefining marine biomass, specifically algal biomass, eventual success was 
ultimately dependent on early, clear and correct choices that matched process to desired products; 
and where these were each appropriate to particular algal species. The strategic dimension to marine 
biotechnology was covered by Dermot Hurst from Ireland’s Marine Institute provided insights to 
progress made over recent years in developing Europe’s marine biotechnology community. He 
pointed to the challenges faced by ERA-MBT in developing a strategic roadmap for marine 
biotechnology including understanding how and where marine biotechnology can add value to 
marine biomass and enable a shift from commodity to niche products. 
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Meredith Lloyd-Evans, Managing Director Biobridge Ltd, in his presentation ‘Who is investing in 
Marine Biotechnology’, outlined a diverse international commercial landscape of marine 
biotechnology and described how investments can help SMEs to grow on the back of marine 
biotechnology related inventions. He described the marine biotechnology investment landscape and 
presented  an extensive global overview on public investments in marine biotechnology. Helena 
Vieira of the University of Lisbon addressed the innovation challenge and potential of marine 
biotechnology. She described scientists as entrepreneurs whose inventive skills can contribute to  
societal expectations from marine biotechnology to be met. She indicated where the critical 
innovation points emerged and further elaborated on how successful entrepreneurship and 
innovation could be achieved. 
From a commercial perspective, access to and the right to exploit marine organisms is important. 
Arianna Broggiato of Université catholique de Louvain described the relevance of the Nagoya 
protocol and the relevance of the access and benefit sharing directive to marine biotechnology. She 
explained the new jurisdiction now being implemented and gave some specific examples on how the 
regulatory set-up could be handled at all levels of property rights and protection. Catherine Boyen, 
CNRS-UPMC, Roscoff, France, made a presentation ‘Setting the scene for Training and Education’ 
where she outlined why training and education is such an important issue for marine biotechnology. 
The ERA-MBT recognises the need for improved training and education within marine 
biotechnology, and has launched a web based survey on the mapping of existing training and 
education as part of a gap analysis. 
During the summer of 2014, ERA-MBT launched an “on-line” questionnaire inviting submissions 
from stakeholders about technical transfer practice and policy, funding issues, access to 
infrastructures and IPR/IPP matters. Insights from this process will feed into the strategic roadmap. 
The preliminary results from the survey were presented at the stakeholder meeting by Sigurdur 
Björnsson, RANNIS, Iceland. Among actions identified was the need to bridge the gap between 
academia and industry, and to provide better access for SMEs to existing infrastructures. 
 
WHERE DO WE GO? 
ERA-MBT has already embarked on a process that is designed to deliver a strategic roadmap for 
marine biotechnology. Under the headline ‘Where do we go’, the feedback from stakeholders at this 
meeting constitutes an important input to the process of developing the strategic roadmap. The 
structure of the workshop provided three formal mechanisms to allow feedback from participants; 
through question and answers after the formal presentations, responding to the questions presented 
to the participants in a break-out session, and discussions during the open roundtable forum 
discussion at the end of the stakeholder meeting. 
To fully reflect the diversity of the feedback, stakeholder comments/feedback were organised under 
generic headings that capture the many opportunities to maximise the use of marine biomass; 
describe new product markets and end uses for marine derived materials; research infrastructure; 
marine biomass production and processing; new policy initiatives; funding requirements and 
modalities and human resource development. For each of these headings a number of bullet points 
were recorded, highlighting the feedback from the stakeholders. 
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A specific question asked at the break-out session involved participants being challenged to identify 
and describe possible future scenarios for marine biotechnology. A summary of the participants’ 
response is presented in the report under the generic headings ‘Scientific and technological 
conditions’, ‘Supporting infrastructure’, ‘Market development’ and ‘Policy and funding climate’.  
 
NEXT STEPS OF MARINE BIOTECHNOLOGY ERA-NET 
The first of the ERA-MBT research calls was announced during the Lisbon Workshop. In his 
introduction to the announcement of the call for research proposals, Steinar Bergseth, coordinator of 
ERA-MBT, explained the aims and the background of the first call. Marta Norton, FCT, Lisbon, 
gave details of the practicalities and procedures of the call and explained how participants could  
apply to the call. A total of 14 funding agencies from 11 countries/regions committed around 8 M 
Euro to support projects that will be selected in a two-step application procedure. 
Participants welcomed the broad theme of this call – ‘The Development of Biorefinery Processes for 
Marine Biomaterials’. The ERA-MBT project plans to announce further research calls and the 
Lisbon workshop provided the opportunity for a broad cross section of researchers and industrialists 
to contribute ideas and suggestions for themes and topics to be included in future research calls. A 
summary of the stakeholder feedback is listed in the report where several research themes and topics 
are proposed, and valuable inputs to how the administration of research calls could be improved 
were also received.  
All the stakeholder feedback will be used to inform the future activities of ERA-MBT. 
Topics highlighted during the discussion on future calls included: 
• Sampling marine material and sampling protocols; 
• The challenge of upscaling from discovery to  commercial exploitation;   
• A need for new financial instruments to stimulate enhanced research-industry and industry-
industry collaboration; 
• Using future calls to focus efforts towards elements in the value chain. 
• Creating greater visibility of marine biotechnology; 
• Providing methods that stimulate more young researchers to engage in marine 
biotechnology. 
 
Overall, the stakeholder event was considered as highly successful in addressing strategic issues that 
will be taken into account for further developing ERA-MBT and providing participants with the 
opportunity to expand their research and other collaborative networks. 
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The longest bridge in Europe; the Vasco da Gama bridge in Lisbon, close to the venue where the first 
ERA-MBT stakeholder meeting was held. 
 
INTRODUCTION 
 
 
The first Stakeholder meeting of the Marine Biotechnology ERA-NET (ERA-MBT) was a chance to 
influence the future of the ERA-MBT as it seeks to expand and to reinforce the network of 
researchers, industry, policy makers and funding agencies to support the development of European 
marine biotechnology. This interactive event was open to scientists, companies, policy 
makers/advisors and other key individuals involved in or interested in furthering European Marine 
Biotechnology research and development. 
 
The meeting was held in Lisbon, Portugal, on the 28th and 29th October of 2014, hosted by the 
Portuguese Foundation for Science and Technology (FCT). This successful meeting attracted 100 
participants from a mix of industry, funding agencies, policy makers/advisors and research 
delegates. Interactive sessions gave a chance for participants to provide feedback on opportunities 
and challenges for ERA-MBT to stimulate marine biotechnology research and innovation. The event 
comprised three headline sessions: 
I) State of the Art of Marine Biotechnology 
II) Where do we go? 
III) Next steps of Marine Biotechnology ERA-NET. 
 
This report describes various aspects of the state of the art of marine biotechnology; feedback given 
by the stakeholders on the question of “Where do we go”  and results of roundtable panel discussion 
on the next steps for ERA-MBT. 
Being the first stakeholder meeting arranged by ERA-MBT the feedback will be used in informing  
the future activities of the ERA-NET. As the first joint call was presented at the meeting, and the 
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Participants at the ERA-MBT first Stakeholder meeting in Lisbon, 28-29 October 2014. 
topic had already been set, the management of ERA-MBT was very interested in listening to 
proposals from stakeholders for future call topics. The chapter “Next steps of Marine Biotechnology 
ERA-NET” provides a summary of this feedback. 
Coinciding with the announcement of the first call, ERA-MBT launched a “match-making” service 
to assist applicants to find potential partners for research consortia. This service will be continued 
for the life of the ERA-MBT. Details of how to use the partnering platform are available on the 
ERA-MBT homepage
1
. 
 
 
 
 
 
 
  
                                                          
1
 https://www.submission-marinebiotech.eu/partner-search  
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STATE OF THE ART OF MARINE 
BIOTECHNOLOGY 
 
 
Invited speakers set the stage for the stakeholder meeting in presenting their view of the ‘state of the 
art’ of marine biotechnology. These contributions echoed the title of the meeting ‘Waves of 
Innovation’, - ‘Integrating National Efforts to Build the Future of Marine Biotechnology’ and in 
doing so reflected the goals of the Marine Biotechnology ERA-NET. 
In his welcome address and introduction Steinar Bergseth of the Research Council Norway, the 
coordinator of the ERA-MBT project, invited the stakeholders to actively participate in the debate 
and to contribute ideas on future ERA-MBT activities that would make marine biotechnology a 
significant driving force in shaping the future of Europe. He elaborated on the content of marine 
biotechnology and the biotech toolbox versus  market drivers seen as developing the field. 
 
POLICY PERSPECTIVE 
Jacques Fuchs, Deputy Head of Unit F4 - Marine Resources, DG Research and Innovation, 
European Commission, described the range of EC support actions that contribute to marine and 
maritime development, and how the Jean-Claude Junker led Commission, provides many new 
opportunities for marine biotechnology, since funding for top-level research not only creates jobs, 
but also ensures that technological progress gives a boost to the economy. He further stressed the 
mission of the newly created Marine Unit within DG Research; this mission included not only the 
desire to enhance the competitiveness of Europe in the global “blue economy”, it also implied the 
need to develop a strategic outlook to achieve the short, medium and long-term objectives that inter 
alia included enhancing marine research and innovation performance leading to Europe becoming a 
global reference point for such activities. EU support for unlocking the potential of the seas and 
oceans comes from initiatives in Horizon 2020, through calls that include dedicated marine 
biotechnology themes. 
 
PRODUCT OPPORTUNITIES 
In an enlightening presentation, Torger Børresen of Innovation Fund Denmark, the Danish ERA-
MBT partner, highlighted the market penetration of products originating from the marine 
environment in areas such as biomaterials, food, pharmaceuticals, etc. He emphasised the market 
potential may be significantly expanded by developing a deeper understanding of the marine 
environment and the options to maximize the use of marine biomass. The adoption of an even-more 
strategic approach that would support a “market driven approach” to marine biotechnology would 
bring a greater research focus to marine biotechnology, particularly, the application areas outside the 
marine sector such as  food, health, materials and biomass production. He emphasized that upscaling 
from lab to industrial scale should be given much consideration for successful commercialization to 
be obtained. He further that for an optimal use of any raw material it would be necessary to target 
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several markets in a multi-stream processing approach. This might call for specialized processors to 
work together in clusters, targeting different applications and markets for better support of the 
European bioeconomy. 
 
INTERNATIONAL MARINE BIOTECHNOLOGY ACTIVITY 
Rachael Ritchie, Director, Business Development, Genome, British Columbia in Canada provided 
an international perspective on the state of the art of marine biotechnology. In a wide-ranging and 
stimulating talk, she covered all aspects of the marine biotechnology value chain from addressing 
the need for expanding the –omics toolbox to the investment potential, governance challenges, 
sustainability and impacts on global needs. Developing a strategic response to rapidly changing and 
diverse environments such as those served by marine biotechnology is a challenge. It requires a 
constant monitoring of the various markets in order to develop an understanding of where 
organisations fit in and a constant assessment of future opportunities. She described how the 
landscape for marine biotechnology has changed since the 1990’s as our understanding of ocean 
bioresources deepened and interest in exploiting marine biotechnology to unlock their potential 
increased. New markets for marine biotechnology products are opening up and according to Dr 
Ritchie will continue to do so; many enabled by the adoption of new research and technology 
platforms that include – big data analytics, genomics, synthetic biology; the evolution of new tools; 
and enhanced recognition of the potential of marine biotechnology to contribute to meeting global 
needs for food production, human and animal health and novel materials.  
 
BIOPROCESSING CHALLENGES 
An insightful and entertaining contribution to the stakeholder event, Dagmar Stengel, National 
University of Ireland Galway, showed how algal biomass on one side is an excellent material for 
biorefining into a range of products, and on the other side, the ecosystem services they offer. She 
pointed to the need to understand these systems in order to use them sustainably in building the 
bioeconomy. She strongly pointed to the concept of a strategy for marine biotechnology. This was in 
the context of describing the challenges in biorefining marine biomass, specifically algal biomass, 
where eventual success was ultimately dependent on early, clear and correct choices that matched 
process to desired products; and where these were each appropriate to particular algal species. 
 
A STRATEGIC DIMENSION TO MARINE BIOTECHNOLOGY 
Dermot Hurst from Ireland’s Marine Institute provided insights to progress made over recent years 
in developing Europe’s marine biotechnology community. He pointed to the challenges faced by 
ERA-MBT in developing a strategic roadmap for marine biotechnology including understanding 
how and where marine biotechnology can add value to marine biomass and enable a shift from 
commodity to niche products. Developing new insights from across the scientific, policy and 
industrial communities in events as this stakeholder meeting will enhance our understanding of the 
 | 10 
 
FIRST ERA-MBT STAKEHOLDER MEETING REPORT 
contribution of marine biotechnology across many industry sectors, and help to shape new funding 
mechanisms to support collaborative research. 
Dr Hurst was a member of the expert panel that met in Bremen in 2007 to discuss the future of 
marine biotechnology and produced the report from that meeting for the EC
2
. Despite the excellent 
progress by way of increased visibility of marine biotechnology, new policy direction and dedicated 
research funds for marine biotechnology and related research, many of the challenges highlighted in 
Bremen remain. Amongst the most challenging of these and the focus of the ERA-MBT objectives 
and the development of a strategic roadmap are defining and prioritising Europe’s future marine 
science and marine biotechnology research activity; securing a greater participation by industry as a 
potential user of outputs from marine biotechnology research; improving the funding and co-
ordination of marine science and targeting resources at marine biotechnology; and encouraging 
Europe’s best scientists to engage in marine biotechnology research. 
 
INVESTMENTS IN MARINE BIOTECHNOLOGY 
Meredith Lloyd-Evans, Managing Director Biobridge Ltd, in his presentation ‘Who is investing in 
Marine Biotechnology’, outlined a diverse international commercial landscape of marine 
biotechnology and described how investments can help SMEs to grow on the back of marine 
biotechnology related inventions. He gave an overview of what the investment landscape looked like 
and presented an extensive overview on public investments in marine biotechnology all over the 
world. Considering different streams for marine biotechnology production he illustrated how 
successful commercial development had been achieved in each of the streams, covering 
bioprospecting, functional food and cosmetics, novel enzymes, algal technologies and upgrading of 
fisheries and aquaculture by-products. 
 
MARINE BIOTECHNOLOGY – AN OPPORTUNITY TO INNOVATE 
Helena Vieira, of the University of Lisbon addressed the innovation challenge and potential of 
marine biotechnology in describing scientists as entrepreneurs whose inventive skills need to be 
realised to meet the societal expectations from marine biotechnology. She raised the central question 
‘how do you go from science to market’? Reflecting how business cycles moved from short to long 
term growth, she indicated where the critical innovation points emerged and further elaborated on 
how successful entrepreneurship and innovation could be achieved. In principle the innovation 
processes in marine biotechnology is not substantially different from other sectors, so a lot may be 
learned from what has been achieved elsewhere. The most important point is to have the right people 
and to train entrepreneurial minded marine biotechnology scientists. 
 
                                                          
2
 
http://www.marinebiotech.eu/sites/marinebiotech.eu/files/public/library/MBT%20publications/2007%20Br
emen%20Marine%20Biotechnology.pdf  
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ACCESSING MARINE RESOURCES 
Arianna Broggiato of Université catholique de Louvain described the relevance of the Nagoya 
protocol and the relevance of the access and benefit sharing directive to marine biotechnology. She 
explained the new legislation now being implemented and gave some specific examples on how the 
regulatory set-up could be handled at all levels of property rights and protection. A practical guide 
would comprise several steps for collectors, which she outlined in her presentation. She further 
stressed the importance of those involved in related research to continue to deepen their 
understanding of future responsibilities regarding access and benefit sharing. 
 
TRAINING IN MARINE BIOTECHNOLOGY 
Catherine Boyen, CNRS-UPMC, Roscoff, France, made a presentation ‘Setting the scene for 
Training and Education’ where she outlined why training and education is such an important issue 
for marine biotechnology. She referred to several reports and recommendations having emphasised 
marine biotechnology as a rather ‘young’ research and development area, it is very important that 
specific educational offers are presented to students and young researchers. One central 
recommendation  of the Marine Board Position Paper 15
3, stated that ‘training the next generation of 
marine biotechnologists must focus on the use of interdisciplinary and holistic approaches to solve 
technological problems specific to dealing with marine organisms and the marine environment’. The 
CSA MarineBiotech that preceded the ERA-MBT also emphasised that the ERA-MBT should 
support training activities such as master classes, courses, summer schools, etc. on marine 
biotechnology related topics. 
The ERA-MBT recognises the need for improved training and education within marine 
biotechnology, and has launched a web based survey to map existing training and education as part 
of a gap analysis. During her presentation, Catherine illustrated the survey content and how to 
respond to it.. Following the analysis of the responses, a list of training options will be made 
available via the ERA-MBT homepage.  
The break-out session asked specific questions on education (Table 10, Annex 3). The feedback 
from this session is summarised in the chapter ‘Human resource development’ in  this report.  
 
INDUSTRY FEEDBACK, AN ON-LINE QUESTIONNAIRE 
During the summer of 2014, ERA-MBT launched an “on-line” questionnaire inviting submissions 
from stakeholders about technology transfer practice and policy, funding issues, access to 
infrastructures and IPR/IPP matters. Insights from this process will feed into the strategic roadmap.  
The preliminary results from the survey were presented by Sigurdur Björnsson from RANNIS, 
Iceland. Respondents from 24 countries represented a range of stakeholders from both the public and 
the private sector; about 80% of the industry contributors describing themselves as SMEs. Whilst 
                                                          
3
 http://www.esf.org/publications/marine-sciences.html 
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these firms processed different types of biomass, the majority of products produced related to the 
food/feed market and the health, pharmaceutical and cosmeceutical markets. The major bottlenecks 
to funding were seen as limited access to domestic public funding, and to EU/international funding. 
Among actions identified was the need to bridge the gap between academia and industry, and to 
provide better access for SMEs to existing infrastructures. 
 
 
Participants during the plenary session at the first ERA-MBT Stakeholder meeting in Lisbon. 
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WHERE DO WE GO?   
 
 
A STRATEGIC APPROACH TO MARINE BIOTECHNOLOGY 
ERA-MBT has already embarked on a process that is designed to deliver a strategic roadmap for 
marine biotechnology. Underpinning this strategic process is a broadly agreed vision for ERA-MBT; 
to support Europe’s marine biotechnology community to participate in a lasting enterprise-driven 
network that adds value to marine biological resources in ways that nurture and sustain the lives 
of European citizens.   
The feedback from stakeholders at this meeting constitutes an important input to the process of 
developing the strategic roadmap. The challenge of developing marine biotechnology capabilities is 
thus not new. European policy and industry interests, together with a diverse and active research 
community, engaged in different actions designed to clarify, and ultimately define, the steps needed 
to make the promise of marine biotechnology a reality. Over recent years the EU and the Marine 
Board assumed a lead role in seeking a more strategic approach to the evolution of marine 
biotechnology. Since the publication of the Marine Board Position Paper 15
4
, the EU sought to 
clarify marine biotechnology in the context of a broader bioeconomy and subsequently in a more 
targeted policy outlook on the marine sector within an overarching strategy termed “Blue Growth”. 
The ERA-MBT strategic planning process is further supported by activities to secure feedback from 
the ERA-MBT including an extensive desk study, completed as part of the ERA-MBT project; 
contributions from an International Advisory Group and a planned foresight exercise termed 
OUTLOOK, which will consider how marine biotechnology might contribute to the realisation of 
the societal challenges that face Europe in 2030.  
 
STAKEHOLDER FEEDBACK 
The structure of the workshop provided three formal mechanisms to allow feedback from 
participants. 
• Ample time for question and answers afforded opportunities for debate after the formal 
presentations and key-note talks. 
• Responding to the questions presented to the participants in a break-out session. 
• The open roundtable forum discussion at the end of the stakeholder meeting. 
 
The break-out session followed the ‘world-café’ model, where participants were asked to visit seven 
different tables (from a total of ten) for group discussions on present questions, according to a pre-
set schedule. The questions discussed in the break-out are presented in Appendix 3 to this report. 
                                                          
4
 http://www.esf.org/publications/marine-sciences.html  
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Participants during the break-out sessions at the first ERA-MBT Stakeholder meeting in Lisbon, which 
was a chance for participants to influence the future of the ERA-MBT. 
 
The roundtable discussion in which the workshop 
participants interacted with the panel members on the 
future challenges and opportunities for ERA-MBT. 
 
During the break-out session, participants described a wealth of opportunities to investigate and 
make use of marine origin bioresources. In doing so, they described areas of opportunity, many of 
which were far removed from typical marine applications. The approach of focussing on industry 
sectors that could utilise marine biotechnology enabled products and processes, significantly 
expands the spread of end-use/applications away from traditional areas. This shift in outlook was 
accompanied by a perspective that sees marine bioresources as offering unique opportunities; worthy 
of exploring in their own right, as opposed to looking upon them as a source of terrestrial 
equivalents.  
      
 
The roundtable discussion was moderated 
by Dermot Hurst. In his introduction he 
encouraged the audience to provide 
feedback that could be used in further 
planning the strategic roadmap. 
Supporting this interaction was a panel of 
members of the ERA-MBT project -  
Petra Schulte, Jülich, Germany, 
Catherine Boyen, CNRS-UPMC, 
Roscoff, France and Sigurdur Björnsson, 
RANNIS, Iceland. Each of the panel 
members made short statements inspiring 
the roundtable dialogue with the audience. 
 
Participants provided extensive feedback throughout the workshop by the different mechanisms 
outlined above. To fully reflect the diversity of the feedback, stakeholder comments/feedback are 
organised under generic headings that seek to capture the many opportunities to maximise the use of 
marine biomass; describe new product markets and end uses for marine derived materials; research 
infrastructure; marine biomass production and processing; policy initiatives; funding requirements 
and modalities and human resource development. 
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Opportunities to maximise the use of marine biomass 
With the marine environment widely recognised as a unique space capable of yielding unique 
bioactive molecules, the search for novel materials from marine organisms continues. The 
development of devices such as remotely operated vehicles is behind a renewed focus on 
bioprospecting. It is now possible to both observe and capture marine organisms from the ocean 
floor. Expanding the exploration of marine environments (some of which had previously remained 
out of reach), is beginning to provide researchers with access to materials from novel marine 
organisms. Traditional and more accessible biomass includes algae – both macro and micro-algae, 
finfish and shellfish. However, despite the familiarity of these materials, they still offer considerable 
scope for the discovery of novel bioactives and other materials and remain high on the research 
agenda. The pressures on stocks as a result of wild harvesting marine species were not viewed as 
sustainable, whilst managed and controlled culturing offered significant benefits, including the 
potential to adjust or manipulate the production of bioactives. Opportunity areas identified by 
participants included: 
• Bacteria from deep sea sediments 
• Microbial symbionts from sponges and other organisms 
• Marine fungi 
• Macro and micro algae 
• Fish processing discards 
• Sponges, cnidarians and other marine invertebrates 
• Bivalves (clams, oysters, mussels, scallops, worms etc) 
 
New product markets/uses for marine derived materials 
Only a small fraction of marine biomass is presently used outside the food and feed sectors. The 
workshop challenged the traditional view of marine biotechnology as limited in applications and 
constrained to existing markets, by identifying emerging opportunity areas and completely novel 
applications for marine derived compounds. The healthcare sector, with some degree of success, 
targeted marine derived molecules as new pharmaceutical entities, as did the nutritional food 
ingredients/supplements sector in developing functional ingredients and nutraceuticals. The marine 
is home to a myriad of exotic biological materials that may inspire biomimetic materials of interest 
to the engineering and medical devices sectors. Not only is the marine proving to be the source of 
new product applications, considerable scope exists for the marine to contribute new processing 
methods. The range of biodiversity found in the marine environment is an excellent source of 
diverse biocatalysts. Initially pioneered by the foods sector, marine derived enzymes have attracted 
the attention of the chemical, pharmaceutical, cosmetics, agriculture and environmental sectors. The 
broad potential use of marine derived materials is reflected in the range of applications identified by 
stakeholders and described below. 
• Biopolymers for use in medical and engineering applications 
• Enzymes for food, pharmaceutical and other process applications 
• Biosensors based on marine organisms and derived materials 
• Food and nutritional ingredients for human and animal health 
• Aquaculture feedstock  
• Anti-fouling compounds 
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• Compounds for cosmetics and cosmeceuticals 
• Nutraceuticals and nutritional supplements 
• Medical devices, including drug delivery, bone and tissue replacement/reinforcement 
• Regenerative medicine 
• High performance adhesives 
• Nanomaterials and nanotechnology  
• Environmental remediation and waste recycling 
• Model organisms and biological assays 
• Pharmaceutical compounds and fine chemicals  
• Traceability of marine food products  
 
Research infrastructure requirements 
Developing and maintaining a marine biotechnology community, which attracts and embraces 
researchers of different disciplines, faces many challenges. Establishing a platform between 
researchers and the array of end-users is essential in stimulating innovation.  Rightly, expectations 
about enhancing the available research infrastructure to support product and process innovations 
have to be met; so too must access to essential core infrastructure. Opening up, expanding and 
creating new infrastructure will serve to broaden marine biotechnology research activity as well as 
attract industry collaborations. Stakeholder feedback highlighted the following areas as priorities in 
reinforcing Europe’s marine biotechnology infrastructure.   
• Create a European marine bioresources database including the results of all evaluations and 
bioassays of compounds  
• Establish repositories for marine organisms, extracts and molecules  
• Develop common collection and sampling platforms 
• Provide new tools to support “rapid” screening activity 
• Broaden use and knowledge of “omics” in marine biotechnology and in screening  
• Create environments that enable the production of targeted secondary metabolites  
• Develop diagnostic tools to assess structural and functional characteristics of organisms 
• Strengthened bioinformatics support for marine  
• Large scale infrastructure – research vessels, ROVs, for deep water and other 
collection/sampling platforms, e.g. autonomous vehicles for seabed sampling 
• Enhanced knowledge of the diversity and distribution of marine organisms in European 
waters 
 
Marine biomass production and processing 
Marine biomass comprises many forms. Typically whole fish, discards from fish capture, farming 
and processing, and macro-algae formed the major source of marine biomass.  Increasingly, biomass 
reflects the diversity of marine biota including e.g. micro algae, marine invertebrates and marine 
microorganisms. Irrespective of the end application, the input to the value-adding conversion 
process is marine biomass.  Securing sufficient biomass presents challenges, particularly if the sole 
source is wild stocks, where overexploitation can threaten the survival of species.  Consistency, 
security and quality of supply have to be balanced in ways that address the environmental 
challenges. The well-managed and controlled culture of marine biomass, whilst similarly facing 
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production challenges, offers a more sustainable source of biomass. The constraints and 
opportunities of biomass processing and production, as identified by contributors to the workshop, 
point to wide-spread concerns regarding how biomass is cultured and harvested and from where as 
outlined below. 
• Novel extraction techniques and facilities 
• Pilot scale equipment for scale-up  
• Selective cultivation and harvesting of marine biomass 
• Develop customised reactor technology to simulate harsh/hazardous environments 
• Use of nanotechnologies for the sampling of micro-organisms and molecules 
• Molecular breeding  
• Synthetic biology as applied to marine biotechnology 
• Land based culture – including land based multi-trophic culture 
• Common platforms for testing marine origin compounds 
• Off shore and deep water aquaculture 
• Novel hosts within which to cultivate microorganisms 
• Enhanced metabolic engineering  
• Creation of common reference/calibration methods for bioactivity  
• Novel processing and processes to strengthen and enhance biorefining  
• Broadened use of genomics to investigate macro- and micro-algae 
 
New policy initiatives 
European policy concerning the bioeconomy generally, and marine biotechnology specifically, 
despite being well developed, is under constant and ongoing review.  This positive approach to the 
provision of a policy framework to encourage and sustain the development of European based 
marine biotechnology activity was highlighted in invited presentations.  The positive policy position 
on marine biotechnology is visible in elements of the Horizon 2020 work programme.  This 
particular focus to the role of marine biotechnology research in respect of food security and health – 
both human and animal, and to bioprocessing, is an acknowledgement of the importance of 
generating new knowledge to support innovation. Cross-cutting marine research is at the heart of 
Horizon 2020, where new knowledge from supported projects, is seen as contributing to the 
European Commission “Blue Growth” initiative and to supporting high-value added products, long-
term growth and jobs. Despite the strong policy footing underpinning marine biotechnology, 
participants identified further opportunities that could be realised, if supported by new policy 
direction: these included 
• Support for the concept of a market for marine extracts 
• Establish common regulatory frameworks for the harvesting and cultivation of marine 
bioresources  
• Enhanced funding schemes to attract multi-disciplinary projects 
• Policy to address the challenges of implementing the Nagoya protocols 
• Build on existing bilateral agreements and stimulate agreements with specified countries 
• Support for regional marine biotechnology activities and a common European information 
base 
• Strengthening the understanding of marine biotechnology by public awareness 
 | 18 
 
FIRST ERA-MBT STAKEHOLDER MEETING REPORT 
• Clarify ownership and use of marine bioresources, including rights to commercialise them 
• Promote a common understanding of marine biotechnology 
• Prioritise funding for marine biotechnology related infrastructure 
• Create schemes to support smaller scale focused projects as a means of building research 
capacity 
• Establish common rules to govern European research funds for marine biotechnology and 
encourage SME participation in projects 
• Marine spatial planning to take account of marine biotechnology needs 
 
A collaborative environment for marine biotechnology 
Knowledge, skills and creativity were identified as the core assets of the modern economy. Assets as 
these, that are critical to business success and economic performance, are the basis of marine 
biotechnology enabled innovation. Against this background, the traditional economic factors of 
labour and capital, according to participants, begin to diminish in importance. In the face of 
scientific and technological globalisation, stimulating interaction between researchers and industry 
was seen as contributing to innovation performance.  The importance of a collaborative outlook and 
response was seen as crucial in enabling marine biotechnology based innovation. Major research 
support programmes increasingly encourage institutional and industry collaboration, which is 
indicative of the beneficial aspects of collaborative research in both the generation and application of 
knowledge. Stakeholder feedback provided many examples of opportunities for increased 
collaboration in marine biotechnology including, 
• Establish links between Europe and leading biotechnology centres of the world 
• Form strategic partnerships with specified countries 
• Establish links and coordination activity between marine biotechnology related research 
platforms, e.g. other ERA-NETs 
• Promote and support marine biotechnology research and innovation clusters 
• Encourage and provide support for global collaboration including additional funds for ERA-
NETs 
• Involve industry associations such as EuropaBio in marine biotechnology initiatives 
• Greater support for marine biotechnology proof of concept projects by SMEs 
• Greater support to encourage European scale collaborative bioprospecting 
• Use pre-competitive R&D projects as the basis for early stage collaboration  
• Support for projects that include multi-disciplinary approaches to marine biotechnology 
projects, including activity that incorporates expertise from outside traditional marine 
biotechnology disciplines and industry 
 
Human resource development 
The skills required to understand, harness and develop marine biotechnology initiatives are many.  
Whist opportunities for “discovery science” exist in the marine biotechnology space, the skill sets 
required to realise them are changing. New analytical and visualisation techniques are being 
developed; many of which are applicable to marine biotechnology. Attracting researchers from other 
disciplines to apply their skills to marine biotechnology is important; but so too is ensuring training 
initiatives can support the development of people with the required competencies. Developing the 
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non-technical competencies to work within new organisational structures are equally important to 
possessing scientific or engineering skills to work on marine biotechnology projects. Participants 
considered education and training as relevant to the academic and business/industry environments 
and stressed the importance of marine biotechnology adopting new training methods. The following 
reflect the broad views of participants on marine biotechnology related education and training needs.  
• To engage in activity that will clarify the role of education and training in support of marine 
biotechnology and identify centres and institutions across Europe that provide such supports 
• Include modules on entrepreneurship and creativity in all post-graduate training 
• Provision of “soft-skills” training for marine biotechnologists – project management, 
communications, teamwork  
• Persons with expertise and backgrounds in biotechnology are relevant to marine 
biotechnology 
• Marine biologists would benefit from training and exposure to biotechnology  
• Provision of industrial placements for postgraduate level scientists and programmes to 
facilitate industry/academia exchange for more senior staff 
• Development of dedicated initiatives designed to generate a greater awareness of the 
potential opportunities for marine biotechnology to contribute to society 
• SMEs targeted in programmes that create awareness of opportunities to benefit from marine 
biotechnology research outputs 
• Stimulate joint actions between industry and academe to define joint training needs  
 
Future possibilities, directions challenges and hurdles  
A specific question asked at the break-out session involved participants being challenged to identify 
and describe possible future scenarios for marine biotechnology (Table 8, Appendix 3). The context 
to this activity was a foresight type exercise being planned by ERA-MBT. Participants in the break-
out session were invited to consider and discuss the “future possibilities, directions, challenges and 
hurdles” likely to impact on the development of marine biotechnology. A summary of the 
participants’ response, organised under generic headings, is given below. 
 
Scientific and technological  
• Major developments in bioinformatics, sequencing and chemical analysis, including the 
development of enhanced visualisation techniques will enable an increase in the rate of 
discovery of new compounds 
•  “Omics” technologies will dominate future RTDI activity and create opportunities for the 
further development of the marine biotechnology toolbox, new products and industrial 
processes 
• There will be a shift away from the serendipitous approach to marine biodiscovery to a more 
rational approach that is based on new predictive techniques to allow for improved targeting 
and better planning of sampling effort  
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Supporting infrastructure 
• The widespread availability of integrated open access databases, and repositories of 
biological and genetic resources will stimulate collaboration between researchers, industry 
players and between industry and researchers, all existing samples will be routinely archived 
for future research 
• New financial instruments that stimulate inter-firm collaboration and also provide support 
for the facilitation of research/industry interaction will become available 
• The various bottlenecks and other challenges encountered in scaling-up from laboratory to 
production level outputs will be solved and organisms previously considered as non-
culturable, will be cultured  
• Despite the likely RTDI process improvements, the need for industry to maintain a balanced 
portfolio of short, medium and long-term research and development projects targeting “low-
hanging fruit” and blue-seas research will remain 
 
Market development 
• Niche markets for marine derived and marine biotechnology enabled products will provide 
the greatest market opportunity for SMEs and these products will result from anticipated 
improved and faster RTDI cycles and the deployment of new research tools and 
infrastructure 
• Priority areas for marine biotech research will remain health and food (human and animal) 
products with alga and fish production becoming the major sources of proteins for food use 
• Society will remain sceptical regarding outputs from genetic research and its impact on 
food, health and the environment 
 
Policy and funding climate 
• The expectations surrounding the impact and contribution of marine biotechnology to 
economic and societal progress in general will be better managed, leading to high levels of 
confidence in industry and amongst consumers, concerning marine biotechnology enabled 
products and processes  
• A wide acceptance of the concept of “open innovation” will enable a wider use of marine 
biotechnology based materials in novel products and processes  
• Marine special planning etc will have recognised, taken into account and created space for 
marine biotechnology and in doing so will establish marine biotechnology as contributing to 
the development of balanced development within coastal regions 
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Steinar Bergseth, explaining the aims and 
background of the first call. 
 
NEXT STEPS OF MARINE BIOTECHNOLOGY  
ERA-NET 
 
 
Feedback from the stakeholder workshop will be used to inform future activities of the ERA-NET.  
In the first instance, feedback from the Lisbon meeting will contribute to defining the strategic 
roadmap. The experiences in managing the first call will influence any future calls from ERA-MBT; 
and responses from surveys on industry needs, training opportunities and findings of the ERA-MBT 
foresight process termed OUTLOOK will each contribute to the question of “Where do we go?”  
 
MARINE BIOTECHNOLOGY RESEARCH PRIORITIES  
Managing the first call for research proposals 
The first of the ERA-MBT research calls was 
announced during the Lisbon Workshop. In his 
introduction to the session where the call was 
presented, Steinar Bergseth, coordinator of 
ERA-MBT, explained the aims and the 
background of the first call. A major aim would 
be to bring together basic, applied, technology 
and market driven research approaches, and 
further to develop new and/or improved 
biotechnological knowledge, tools and methods 
for the sustainable processing of marine biomass. 
The final target would be to obtain a variety of 
bio-based products and/or services through 
integrated biorefinery processes ideally utilising all molecular fractions present in the relevant 
biomass. 
Marta Norton from FCT, Portugal, gave a detailed presentation on the practical details and 
administrative procedures connected with the first call and explained how participants should  make 
applications. A total of 14 funding agencies from 11 countries/regions agreed to contribute a total of 
€8 million to stimulate marine biotechnology research. The final outcome of what is a two-step 
application and evaluation process is expected by end of July 2015. Lively discussions between 
prospective partners' intent on bidding for a slice of the funds from the first call for research 
proposals were a feature of coffee breaks. 
 
Future research calls 
Participants welcomed the broad theme of this call – ‘The Development of Biorefinery Processes for 
Marine Biomaterials’. The ERA-MBT project plans to announce further research calls as the project 
proressses. A range of inputs will influence the content of these future calls including the ERA-MBT 
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strategic roadmap, industry questionnaires and direct feedback from stakeholder events. The Lisbon 
workshop provided the opportunity for a broad cross section of researchers and industrialists to 
contribute ideas and suggestions for themes and topics to be included in future research calls.  
 
Stakeholder feedback on calls and projects 
During the round table discussion participants made valuable contributions concerning the 
promotion and administration of research calls and future call topics. A summary of the stakeholder 
feedback, reflecting the views of industry, policy and research communities is given below. 
 
Research themes and topics 
• The sustainable production of biomass; including marine animals, algae, bacteria etc. with a 
view to delivering secure and high quality supplies of biomass that meet the requirements of 
the processing/refining sector  
• Demonstrate the use “state of the art” tools and methodologies to obtain genetic information, 
including whole genomes, of marine species of commercial interest 
• Marine biotechnology projects can encounter problems in shifting from laboratory to pilot 
scale, hence there is a need to investigate the challenge of up-scaling biomass production 
• There are many opportunities to target existing markets in the human and animal food, feed, 
nutritional ingredients and ingredients for cosmetics; projects that target these so-called 
“low-hanging fruits” can demonstrate benefits of marine biotechnology as well as generate 
early cash flows. 
• The development and use of new tools and analysis methods to support molecular 
aquaculture 
• Provide test and demonstration sites for biorefining and other capital intensive processing of 
marine biomass and make them available to a broader potential user base.   
• Use of high throughput screening and analysis methods for marine extracts – targeting 
biochemical functionality 
• Create a pilot marine biomaterials repository and supporting database providing details of 
organisms, extracts and performance of bioactives and other compounds as the “blue-print” 
for network repositories and define the requirements for a common European marine 
bioresources database.  
• Support the creation of links to other networks where competencies are relevant to the 
objectives of marine biotechnology – e.g. supporting the production of marine biomass or 
providing access to large scale research infrastructure.  
• Support projects that involve interaction of ERA-MBT with industrial biotechnology ERA-
NETs in ways that enable marine biotechnology projects to gain access to the array of tools, 
techniques and methodologies 
• Provide funds to support for marine biotechnology proof of concept studies. 
• Fund research facilities to open access to  industry to engage on joint projects 
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Administration of research calls 
• Establish ERA-MBT as an information and knowledge hub for communication and 
interaction with researchers and industry, building links to other ERA-NETs and networks 
links to with information sources. 
• Identify and support potential partners from outside Europe to participate in ERA_MBT 
projects with a view to strengthening European marine biotechnology research. 
• Ensure project submissions are more specific (more definition of tasks, sub-tasks, 
deliverables etc) and project teams more accountable for the delivery of agreed results, by 
introducing stricter project management guidelines.  
• Increase the scope for industry to participate at all stages in the definition and approval of 
ERA-MBT projects. 
• Create a separate fund that would encourage the next generation and emerging high-
potential research to lead marine biotechnology projects. 
• Support innovative ERA-MBT researchers to form links with a company including spending 
time located within companies where knowledge transfer would be rewarded by exposure of 
the researcher to in-company business/commercial activity.  
• Support Erasmus Mundus master degree in Marine Biotechnology  
• Support promotion and awareness creation projects, including the award of a European wide 
prize to a high-performing emerging marine biotechnology researcher 
 
 
In summary, the stakeholder event was considered as highly successful in highlighting strategic 
issues that will be taken into account in further developing ERA-MBT and also providing 
participants with the opportunity to expand their research and other collaborative networks.  Some of 
the major issues highlighted in the open forum reflect the diversity of the large and enthusiastic 
attendance including , 
• Sampling marine material and sampling protocols; 
• The challenge of upscaling from discovery to commercial exploitation;  
• A need for new financial instruments to stimulate enhanced research-industry and industry-
industry collaboration; 
• Using future calls to focus efforts towards elements in the value chain; 
• Creating greater visibility of marine biotechnology; and 
• Providing methods that stimulate more young researchers to engage in marine 
biotechnology. 
 
Presentations, a news report and a photo gallery from the stakeholder meeting are available at 
www.marinebiotech.eu/stakeholder-meeting. 
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APPENDICES 
 
 
APPENDIX 1: PROGRAMME 
First Marine Biotechnology ERA-NET Stakeholder Meeting 
WAVES OF INNOVATION 
Integrating National Efforts to Build the Future of Marine Biotechnology 
28
th
 - 29
th
 October 2014, Olissippo Oriente Hotel, Lisbon, Portugal 
Tuesday 28 October 2014 
Session 1 State of the Art of Marine Biotechnology 
Chair: Steinar Bergseth 
 
09:00 Welcome to meeting and introduction to Marine Biotechnology 
Steinar Bergseth, RCN, Norway, Coordinator 
 
09:30 Introduction to Marine Biotechnology – The market driven approach 
Torger Børresen, IFD, Denmark 
 
10:00 Vision on marine biotechnology Research and Development as seen from the 
European Commission 
Jacques Fuchs, Deputy Head of Unit, DG RTDI, Marine Resources 
 
 
10:30 Coffee break 
 
 
11:00 Marine Biotechnology: Enabling Solutions for Ocean Productivity and 
Sustainability 
Rachael Ritchie, Director, Business Development, Genome British 
Columbia, Canada 
 
11:40 The results, conclusions and further needs in the ERA-MBT stakeholder survey  
Sigurdur Bjørnsson, RANNIS, Iceland 
 
 
12:00 Buffet Lunch & networking 
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Session 2 Where do we go? 
Chair: Torger Børresen 
 
14:00 Requirements for successful innovation from marine biotechnology 
Helena Vieira, Consultant, SELF, Faculty of Sciences, University of Lisbon 
 
14:30 Access and benefit sharing according to the Nagoya protocol – what does it mean 
for marine biotech? 
Arianna Broggiato, Postdoctoral Researcher, Univerité catholique de 
Louvain. 
 
   
----------------------------------------------------------- 
 
 
15:00 Workshop sessions in break-out groups 
Participants will be presented with specific topics to express their views 
on. The ERA-MBT will analyse and incorporate these as appropriate in the 
development of new calls, communications and strategies. 
 
17:30 Plenary Sum up of ideas from the workshop sessions 
  Torger Børresen, IFD, Denmark 
 
 
19:00 Buffet dinner & Networking 
 
Panoramic room – Tivoli Oriente, Av. Dom João II, nº 27 
(Across the street from Olissippo) 
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Wednesday 29 October 2014 
 
Session 3 Next steps of Marine Biotechnology ERA-NET 
Chair: Dermot Hurst 
 
09:30 Aims of the first ERA-MBT call 
Steinar Bergseth, Coordinator ERA-NET MarineBiotech 
 
09:45 Keynote presentation on Biorefinery of marine biomass 
 Dagmar Stengel, National University of Ireland Galway, Ireland 
 
10:15 Who are investing in marine biotech? 
 Meredith Lloyd-Evans, Managing Director Biobridge Ltd 
 
10:35 How to participate in the first call – practical details and procedures 
 Marta Norton, FCT, Portugal 
 
  
11:00 Networking coffee break 
 
 
11:30 Setting the scene for Training and Education 
Catherine Boyen, CNRS, France 
 
11:50 Challenges for a Strategic Roadmap on marine biotechnology 
 Dermot Hurst, Marine Institute, Ireland 
 
12:15 Roundtable discussion of proposed conclusions from the workshop session at day 1 
Moderator: Dermot Hurst, Marine Institute, Ireland 
Participants: Representatives from academia and industry 
 
12:50 Wrap up & next steps 
 Steinar Bergseth, RCN, Norway, Coordinator 
 
13:00 Adjourn & lunch 
 
A ‘wishbox’ will be provided at the conference venue, where participants can post 
written statements for future actions. 
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APPENDIX 2: PARTICIPANTS LIST 
List of participants 
First Marine Biotechnology ERA-NET Stakeholder Meeting 
 
WAVES OF INNOVATION 
Integrating National Efforts to Build the Future of Marine Biotechnology 
28
th
 - 29
th
 October 2014, Olissippo Oriente Hotel, Lisbon, Portugal 
 
AGUAR FERNANDEZ Maria Pilar, European Commission (EC Joint Research Centre), Italy 
ALMEIDA Cheila, FCUL - CENSE (FCT-UNL) - SIK (FCUL - CENSE (FCT-UNL) - SIK), Portugal 
AMORIM Ana, Marine and Environmental Sciences Centre, Faculdade Ciências Universidade Lisboa 
(MARE-FCUL), Portugal 
ARENTS Inge, Agency for Innovation by Science and Technology (IWT), Belgium 
BARBAS Julio, Ministry of Economy and Competitiveness (MINECO), Spain 
BAVINGTON Charles, GlycoMar Limited (GlycoMar), United Kingdom 
BERGSETH Steinar, The Research Council of Norway (RCN), Norway 
BETTENCOURT Raul, IMAR Center-University of the Azores (IMAR/UAz), Portugal 
BIRKELAND Nils-Kåre, University of Bergen (UiB), Norway 
BJORNSSON Sigurdur, The Icelandic Centre for Research (Rannis), Iceland 
BØRRESEN Torger, Danish Agency for Science, Technology and Innovation (DASTI), Denmark 
BOSSIER Peter, Ghent University, Lab Aquaculture & Artemia Reference Center (Ugent), Belgium 
BOYEN Catherine, Station Biologique de Roscoff CNRS-UPMC (SBR-CNRS), France 
BROGGIATO Arianna, Universitè Catholique de Louvain (UCL), Belgium 
CARLBERG Anders, Region Västra Götaland (VGR), Sweden 
CARRILHO, Dina, Fundação para a Ciência e Tecnologia, Portugal 
COLLARD Fanny, Belgian Institute of Public Health (WIV-ISP), Belgium 
COSTA Gonçalo, BioMimetx (BioMimetx), Portugal 
COZ-RAKOVAC Rozelindra, Rudjer Boskovic Institute (RBI), Croatia 
DE LA CALLE Fernando, PharmaMar (PharmaMar), Spain 
DE RAEDEMAECKER Fien, Flanders Marine Institute (VLIZ), Belgium 
DENARO RENATA, INSTITUTE FOR COASTAL MARINE ENVIRONMENT (IAMC CNR), ITALY 
DURAND Patrick, Pole Mer Bretagne Atlantique (PMBA), France 
EGAS Conceição, Biocant (Biocant), Portugal 
EHRLICH Hermann, Institute of Experimental Physics (TU BAF Freiberg), Germany 
EINARSSON Hjorleifur, Faculty of Natural Resource Sciences, University of Akureyri (UNAK), Iceland 
ELYSEU MESQW Paula, Fundação Ciência e Tecnologia (FCT), Portugal 
ERLENDSSON Lydur Skuli, The Icelandic Centre for Research (Rannis), Iceland 
FERNANDES Maria João, Fundação para a Ciência e a Tecnologia (FCT), Portugal 
FERREIRA Bruno, Biotrend - Inovação e Engenharia em Biotecnologia, S.A. (Biotrend SA), Portugal 
FOWLER Donald, Highlands and Islands Enterprise (HIE), UK Scotland 
FRANCISCO Nélida, FCT - Fundação Ciência e Tecnologia (FCT), Portugal 
FUCHS Jacques, European  Commission (DG RTD), Belgium 
FUCHS Judith, European Marine Biological Resource Centre (EMBRC), France 
FYLLING-JENSEN Oeyvind, Nofima AS (Nofima), Norway 
GAUDÊNCIO Susana, REQUIMTE- Faculdade de Ciências e tecnologia da Universidade Nova de 
Lisboa (REQUIMTE-FCT/UNL), Portugal 
GEBERT MARINA, Fraunhofer Institution for Marine Biotechnology (Fraunhofer EMB), Germany 
GEIRSDÓTTIR Margrét, Matís ltd. - Icelandic Food and Biotech R&D (Matís), Iceland 
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GONÇALVES, Luís, Instituto de Tecnologia Química e Biológica (ITQB), Portugal 
GONZALEZ, David, Ministry of Economy and Competitiveness, MINECO, Spain 
GULLFOT Fredrika, Simris Alg AB (Simris Alg), Sverige 
HAUGEN Peik, UiT-The Arctic University of Norway (UiT), Norway 
HURST Dermot, Marine Institute (Marine Institute), Ireland 
IANORA Adrianna, Stazione Zoologica Anton Dohrn (SZN), Italy 
IMHOFF Johannes, Helmholtz Center for Ocean research (GEOMAR), Germany 
JACOBSEN Charlotte, Technical University of Denmark (DTU Food), Denmark 
JAKOBSEN Greta, Marinova (Marinova), Denmark 
JØRGENSEN Trond Ø., MabCent / University of Tromsø (University of Tromsø), Norway 
KANOBANA Kirezi, Agency for stimulation of Innovation through Science and Technology (IWT), 
Belgium 
KIRCHNER Andree, Institute for the Law of the Sea and International Marine Environmental Law 
(ISRIM), Germany 
KIRCHNER-FREIS Iris, Institute for the Law of the Sea and International Marine Environmental Law 
(ISRIM), Germany 
KLOOSTERMAN Ernst, Industrial Biotechnology Network Norway (IB Network), Norway 
LEBARON Philippe, Observatoire Océanologique de Banyuls s/mer (Observatoire Océanologique de 
Banyuls s/mer), France 
LEMOS Catarina, University of Aveiro (UA), Portugal 
LEMOS Marco, Marine Resources Research Group (GIRM-IPleiria), Portugal 
LIMA Pedro, Sea4Us - Biotecnologia e recursos Marinhos, Ltd (Sea4Us), Portugal 
LLOYD-EVANS Meredith, BioBridge Ltd (BioBridge), United Kingdom 
LOURO, Ricardo, Instituto de Tecnologia Química e Biológica (ITQB), Portugal  
MENDES Rogério, Instituto Português do Mar e da Atmosfera (IPMA, I.P.), Portugal 
MOE Elin, Instituto de Tecnologia Química e Biológica (ITQB), Portugal 
MØLLER Per, Kalundborg Municipality, Dept. Development (KK-Development), Danmark 
MORAN Lisa, National University of Ireland Galway (NUIG Galway), Ireland 
MOREIRA-SILVA Joana, University of Minho - 3B's Research Group (University of Minho), Portugal 
NORTON Marta, FCT - Fundação Ciência e Tecnologia (FCT), Portugal 
PAIS, Teresa, Instituto de Medicina Molecular (IMM), Portugal 
PARDO Daniel, MNHN/CNRS France (MNHN France), France 
PETERSEN Bent, Center for Biological Sequence Analysis (CBS/DTU), Denmark 
PIKER Levent, Coastal Research & Management (CRM), Germany 
PROVAN, Fiona, Organization International Research Institute of Stavanger, IRIS, Norway 
RITCHIE Rachael, Genome British Columbia (Genome BC), Canada 
ROBBENS Johan, Institute for agricultural and fisheries research (ILVO), Belgium 
ROJE Marin, Rudjer Boskovic Institute (RBI), Croatia 
RUDDY Ann, Redrose Developments Ltd (Redrose Developments Ltd), Ireland 
SANCHEZ-PUELLES Jose M., Ministry of Economy and Competitveness (MINECO), Spain 
SANTOS Romana, Biomedical and Oral Sciences Research Unit, School of Dentistry, Univ. of Lisbon, 
Portugal 
SCHIFFERS Jens, Project Management Juelich (PtJ), Germany 
SCHULTE Petra E., Project Management Jülich (PtJ), Germany 
SCOMA Alberto, Gent University (Belgium) (UGent), Belgium 
SEABI Josias masharakane, NRF/NZG (NATIONAL RESEARCH FOUNDATIO), South Africa 
SILVA Helena, Instituto Português do Mar e da Atmosfera (IPMA IP), Portugal 
SILVA Tiago H., University of Minho - 3B's Research Group (University of Minho), Portugal 
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SKARBO Oddvar, AAKP/LEGASEA (LEGASEA), Norway 
STENGEL Dagmar, National University of Ireland Galway (NUI Galway), Ireland 
TASDEMIR Deniz, Helmholtz Center for Ocean Research Kiel (GEOMAR Kiel), Germany 
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APPENDIX 3: QUESTIONS FOR BREAK-OUT SESSIONS 
Table 1 
What tools, techniques, processes and methods are required to support the development of 
marine biotechnology?  
Table Chair Uwe Waller, Co-Chair Margret Geirsdottir 
Background: The development of new tools within molecular biology, like different -omics, is 
considered important for the toolbox needed to release the full potential within marine 
biotechnology. We would like to have views of which of such methods are the most important to 
take up or develop further, and which adaptions that are needed for applications within marine 
biotechnology. Other techniques, like e.g. in information technology, nanotechnology etc. may also 
be considered. 
Table 2 
What are the opportunity areas for marine biotechnology and what resources should be targeted 
to realize these opportunities? 
Table Chair Adrianna Ianora, Co-Chair Julio Barbas 
Background: The areas should support the development of the European bioeconomy, and can be 
considered from the viewpoint of sourcing or raw materials, microorganisms, or biomass like 
macroalgae, microalgae, etc. to derive specific proteins, carbohydrates, lipids, enzymes, etc. 
Another topic categorization can be product derived, like e.g. for pharmaceutical use, 
nutraceuticals, cosmetics, food or feed, or applications related to aquaculture etc. 
Table 3 
Where along the value chains should marine biotechnology research effort be focused or 
targeted? 
Table Chair Sigurdur Björnsson, Co-Chair Renata Denaro 
Background: When considering the development of a specific value chain, gaps are often 
experienced somewhere along the chain. It is known that transferring research results into 
commercial production presents many challenges that may make the original thoughts for a certain 
topic very difficult to pursue. 
Table 4 
What are the relevant indicators that can be used for creating a marine biotechnology success? 
Table Chair Ernst Kloosterman, Co-Chair Inge Arents 
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Background: For any stepwise development of a product it is necessary to set up some indicators 
that should be monitored if the final result is to be a success. These requirements can be related to 
economical calculations relative to anticipated market price for given end products, or it could be 
consideration of certain risk factors or problems that needs to be solved for further progress. In 
addition to financial issues, technical issues or environmental or energy issues may also be 
important. 
Table 5 
What barriers have to be overcome to enable the development of marine biotechnology based 
products, processes and services? 
Table Chair Adrianna Broggiato 
Background: International collaboration may present some problems related to sourcing of the raw 
material, i.e. in which areas are the organisms or a given gene pool originating? Are there 
questions of jurisdiction that should be considered? The right of ownership is another area that 
may be of general concern. Are such concerns specific for marine biotechnology or are they 
general for all technical developments? 
Table 6 
How can collaboration with marine biotechnology stakeholders outside Europe create added 
value to marine bioresources and the development of the toolbox? 
Table Chair Meredith Lloyd-Evans, Co-Chair Rachel Ritchie 
Background: The present project is an ERA-NET, which is suitable for creating added value within 
European marine biotechnology. Are there non-European countries with specific MBT know how 
advances which Europe could profit from? How could projects and strategies be framed to achieve 
the added value embedded in such transnational co-operations and create win-win relations? 
Table 7 
What other European collaboration and funding instruments are relevant to contact for an 
extended networking of ERA-MBT? 
Table Chair Petra Schulte, Co-Chair Marta Norton 
Background: The ERA-MBT has a given work programme, where a strategic roadmap is being 
developed and the final goal is to create a lasting network that is active after the present 4 year 
project period is finished. There are many other collaboration instruments like ERA-NETs, JPIs, etc. 
being active at the time when ERA-MBT is running. Which of these instruments should be 
considered for a closer collaboration in order to pursue the goal of ERA-MBT?  
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Table 8 
What are the future possibilities, directions challenges and hurdles? 
Table Chair Dermot Hurst 
Background: The ERA-MBT is doing a separate and dedicated foresight exercise (named OUTLOOK) 
to inform the roadmap we set out to deliver. We find it very useful to also use the present 
opportunity to do a brainstorming with you as stakeholders to get as many views as possible to 
feed both into the foresight process and also as background for the further ERA-MBT work. During 
the time available for the group, please come up with short statements on areas to work on, issues 
to address, gaps to fill, technical developments needed, societal issues to address, etc… 
Table 9 
Are the current project funding instruments of the EU well aligned to drive marine biotechnology 
projects from good basic science through innovations, to proof of concept and added-value as 
products, processes and services? 
Table Chair Steinar Bergseth, Co-Chair Kim Turk 
Background: The ERA-MBT is seeking to stimulate the creation of, and utilisation of, research based 
innovations. This requires development and uptake of applications in industrial and SME 
environments. The ERA-MBT wants to understand if there are funding instruments to develop for 
MBT that can stimulate this process to run smoother; maybe in particular the interface from an 
academic invention to its further development to an application in a market. 
Table 10 
What education and training requirements need to be provided to support the development of 
marine biotechnology? Needs and gaps within training and education for MBT? 
Table Chair Catherine Boyen Co-Chair Fien De Raedemaecker 
Background: A successful development of MBT is dependent on people with the right competences 
and understanding of the area, the methods and needs for multi-disciplinary approaches. This 
applies both to the academics and industrial environments. Where and how are new knowledge, 
training and interactions important to build for the best of MBT? 
 
